|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the effect of macrophage sortilin on ATP-binding cassette transporter A1 (ABCA1) expression, ABCA1-mediated cholesterol efflux, and aortic AS.
|
30950489 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR‑30e and miR‑92a are related to atherosclerosis by targeting ABCA1.
|
30816508 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, inhibition of CD36-mediated oxLDL uptake and induction of ABCA1- and ABCG1-dependent cholesterol efflux are two working mechanisms by which andrographolide inhibits macrophage foam cell formation, which suggests that andrographolide could be a potential candidate to prevent atherosclerosis.
|
29298513 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For the ABCA1 C69T polymorphism, six studies involving 1854 AS cases and 5744 controls were combined showing significant association between this variant and AS risk (for T allele vs. C allele: OR =1.44, 95% CI =1.04-1.24, p =0.005; for T/T vs. C/C: OR =1.39, 95% CI =1.12-1.73, p =0.003; for T/T vs. C/T+C/C: OR =1.34, 95% CI =1.09-1.65, p =0.006; for T/T+C/T vs. C/C: OR =1.13, 95% CI =1.01-1.27, p =0.040).
|
25527331 |
2015 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Reduced expression of ABCA1, also seen in human intimal SMCs, suggests a common mechanism for formation of SMC foam cells across species, and represents a novel target to enhance atherosclerosis regression.
|
30786740 |
2019 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, chronic whey protein supplementation can improve HFCD-induced atherosclerosis in ApoE null mice by regulating circulating lipid and inflammatory cytokines and increasing expressions of ABCA1 and ABCG1.
|
29710032 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Insufficient ABCA1 activity may lead to increased risk of atherosclerosis due to reduced HDL formation and cholesterol efflux.
|
22811478 |
2012 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here we review the current status of the pathway of HDL biogenesis and mutations in apoA-I, ABCA1, and SR-BI that disrupt different steps of the pathway and may lead to dyslipidemia and atherosclerosis in mouse models.
|
16501936 |
2006 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA 33 (miR-33) targets ATP-binding cassette transporter A1 (ABCA1), and its deficiency increases serum high-density lipoprotein (HDL)-cholesterol (HDL-C) and ameliorates atherosclerosis.
|
29712758 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
ATP-binding cassette transporter A1 (ABCA1) promotes cholesterol and phospholipid efflux from cells to lipid-poor apolipoprotein A-I and plays an important role in atherosclerosis.
|
22005457 |
2011 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Locally in the arterial wall, ABCA1 influences atherosclerosis by acting not only in bone marrow-derived cells but also in endothelial cells and smooth muscle cells.
|
24992457 |
2014 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We describe a patient with a unique phenotype of Tangier disease from a novel splice site mutation in the ABCA1 gene that is associated with a central nervous system presentation resembling multiple sclerosis, and the presence of premature atherosclerosis.
|
23351586 |
2013 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We compared the consequences of an ABCA1 mutation that produced an apparent lack of atherosclerosis (Tangier family 1, N935S) with an ABCA1 mutation with functional ABCA1 knockout that was associated with severe atherosclerosis (Tangier family 2, Leu(548):Leu(575)-End), using primary and telomerase-immortalized fibroblasts.
|
24196952 |
2013 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Associations between two common polymorphisms in the ABCA1 gene and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA).
|
16879828 |
2007 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Intima media thickness studies have provided evidence that hypoalphalipoproteinemia due to mutations in apoA-I, ABCA1, and LCAT is associated with increased progression of atherosclerosis.
|
15767853 |
2005 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cyclosporin A (CsA) is an immunosuppressant that inhibits protein phosphatase 2B (PP2B/calcineurin) and is associated with hyperlipidemia, decreased cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1), and increased risk of atherosclerosis.
|
19589783 |
2009 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Leonurine can promote cholesterol efflux and alleviate cellular lipid accumulation by magnifying the expression of ABCA1/G1 in a PPARγ/LXRα signaling pathway-dependent manner in human THP-1 macrophage-derived foam cells and abate atherogenesis in apoE-/- mice, which may offer a promising therapeutic intervention of leonurine in protecting against AS.
|
29045950 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These combined findings provide insights into ABCA1-mediated regulation of cellular cholesterol metabolism and will facilitate the identification of new pharmacologic agents for the treatment of atherosclerosis in humans.
|
10884428 |
2000 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In hypercholesterolemic <i>ldlr</i><sup>-/-</sup> mice, Cav enhanced serum exosomal ABCA1 expression and suppressed atherosclerosis by inhibiting lipid deposition and macrophage accumulation.
|
31635197 |
2019 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis.
|
16928680 |
2006 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In particular, the relative contribution of hepatic and peripheral ABCA1 to plasma HDL levels and to reverse cholesterol transport, as well as the potential role of ABCA1 in modulating the plasma concentrations of the apolipoprotein B-containing lipoproteins and protecting against atherosclerosis, seem to be promising areas of investigation.
|
12615681 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The ATP-binding cassette transporter A1 (ABCA1) functions as a pivotal regulator of lipid efflux from cells to apolipoproteins and is thus involved in lowering the risk of atherosclerosis.
|
20101560 |
2010 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further studies are needed to elucidate the full function of ABCA1 in the protection against atherosclerosis.
|
23136402 |
2013 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COS treatment attenuated AS and decreased plasma non-HDL level in apoE-/-, and the potential mechanism might be involved with enhanced expression of hepatic LDL-R and SR-BI, and macrophage ABCA1.
|
25843117 |
2015 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent findings have confirmed that APOA1 and ABCA1 exert the strongest influence on HDL concentrations and risk of atherosclerosis.
|
17353664 |
2007 |